U.S. markets closed

Theralink Technologies, Inc. (OBMP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
At close: 1:19PM EDT

Theralink Technologies, Inc.

15000 West 6th Avenue
Suite 400
Golden, CO 80401
United States
888 585 4923
http://www.theralink.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael I. RuxinPres, CEO & DirectorN/AN/A1946
Mr. Thomas E. Chilcott III, CPAChief Financial OfficerN/AN/A1968
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Theralink Technologies, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapy products. The company has proprietary rights to immunotherapy platform focusing on prostate and breast cancers. The company's lead product is ProscaVax, which is in phase 2 clinical trials for the treatment of prostate cancer. It is also developing targeted therapies. Theralink Technologies, Inc. has a partnership with Perthera, Inc. to facilitate and enhance access to Theralink's 32 phosphoprotein panel, the Theralink assay, for breast cancer patients. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc. is based in Baton Rouge, Louisiana.

Corporate Governance

Theralink Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.